Tuesday, March 20, 2012
Genmab A/S, of Copenhagen, Denmark, submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL). Patients in the study will receive ofatumumab plus chemotherapy or Rituxan (rituximab, Biogen Idec Inc. and Roche AG) plus chemotherapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.